CA3235765A1 - Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof - Google Patents

Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof Download PDF

Info

Publication number
CA3235765A1
CA3235765A1 CA3235765A CA3235765A CA3235765A1 CA 3235765 A1 CA3235765 A1 CA 3235765A1 CA 3235765 A CA3235765 A CA 3235765A CA 3235765 A CA3235765 A CA 3235765A CA 3235765 A1 CA3235765 A1 CA 3235765A1
Authority
CA
Canada
Prior art keywords
optionally substituted
heterocycloalkyl
alkyl
cycloalkyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3235765A
Other languages
English (en)
French (fr)
Inventor
Jianping Wu
Luoheng QIN
Jinxin LIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InSilico Medicine IP Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3235765A1 publication Critical patent/CA3235765A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3235765A 2021-11-12 2022-11-11 Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof Pending CA3235765A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/130290 2021-11-12
CN2021130290 2021-11-12
CN2022123827 2022-10-08
CNPCT/CN2022/123827 2022-10-08
PCT/CN2022/131293 WO2023083286A1 (en) 2021-11-12 2022-11-11 Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof

Publications (1)

Publication Number Publication Date
CA3235765A1 true CA3235765A1 (en) 2023-05-19

Family

ID=86335131

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3235765A Pending CA3235765A1 (en) 2021-11-12 2022-11-11 Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof

Country Status (19)

Country Link
US (3) US20250026754A1 (https=)
EP (1) EP4430050A4 (https=)
JP (1) JP2024543477A (https=)
KR (1) KR20240117556A (https=)
CN (1) CN119053601A (https=)
AR (1) AR127646A1 (https=)
AU (1) AU2022386486A1 (https=)
CA (1) CA3235765A1 (https=)
CL (2) CL2024001397A1 (https=)
CO (1) CO2024006269A2 (https=)
CR (1) CR20240191A (https=)
DO (1) DOP2024000080A (https=)
GE (1) GEAP202416532A (https=)
IL (1) IL312642A (https=)
JO (1) JOP20240096A1 (https=)
MX (1) MX2024005755A (https=)
PE (1) PE20241307A1 (https=)
TW (1) TW202334142A (https=)
WO (1) WO2023083286A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20240191A (es) 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
WO2024086790A1 (en) * 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
WO2025227060A1 (en) 2024-04-26 2025-10-30 Insilico Medicine Ip Limited Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337611A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE69921358T2 (de) * 1998-12-23 2006-03-09 Bristol-Myers Squibb Pharma Co. Stickstoffhaltige heterobicyclen als faktor-xa-hemmer
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
ITFR20030005U1 (it) 2003-03-17 2003-06-16 C D R Sistema di protezione solare (frangisole f1)
JP2010208945A (ja) 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
EP2370437B1 (en) 2008-11-25 2013-09-04 Nerviano Medical Sciences S.r.l. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
SG10201407012XA (en) 2009-10-29 2014-11-27 Genosco Kinase inhibitors
US8541418B2 (en) 2009-12-23 2013-09-24 Elan Pharmaceutical, Inc. Inhibitors of polo-like kinase
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US9242981B2 (en) * 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
AU2011376721B2 (en) 2011-09-16 2017-06-08 Sanofi Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
CA2896731A1 (en) 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CN104311555B (zh) 2014-09-19 2016-04-20 广东东阳光药业有限公司 吡唑并哌啶酮类化合物及其组合物及用途
US9763922B2 (en) 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
US10189841B2 (en) * 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
EP3464286B1 (en) 2016-05-24 2021-08-18 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
WO2019089216A1 (en) 2017-11-01 2019-05-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancers
BR112021010715A2 (pt) * 2018-12-20 2021-11-16 Ksq Therapeutics Inc Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)
JP7553450B2 (ja) * 2018-12-28 2024-09-18 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１を阻害するための組成物
CA3168009A1 (en) * 2020-02-14 2021-08-19 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
EP4161494A4 (en) 2020-06-02 2024-07-17 KSQ Therapeutics, Inc. NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS
KR20230098186A (ko) 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
TW202246255A (zh) 2021-02-12 2022-12-01 美商傳達治療有限公司 Ｃｄｋ抑制劑及其使用方法
US20240182481A1 (en) 2021-02-15 2024-06-06 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
AU2022238886A1 (en) 2021-03-17 2023-09-14 Medivir Ab Purine derivatives as anticancer agents
WO2022199652A1 (en) 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
MX2023011709A (es) 2021-04-07 2023-10-12 Forma Therapeutics Inc Inhibidor de la proteasa 1 especifica de ubiquitina (usp1).
EP4321515A4 (en) 2021-04-09 2025-06-25 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. UBIQUITIN-SPECIFIC PROTEASE-1 INHIBITOR
EP4430041A4 (en) 2021-11-12 2025-09-24 Insilico Medicine Ip Ltd SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES
CR20240191A (es) 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
GEAP202416531A (en) 2021-11-12 2024-10-28 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2024086790A1 (en) 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS

Also Published As

Publication number Publication date
GEAP202416532A (en) 2024-08-12
CL2025001068A1 (es) 2025-07-11
US20250026754A1 (en) 2025-01-23
US20240190839A1 (en) 2024-06-13
PE20241307A1 (es) 2024-06-24
MX2024005755A (es) 2024-09-06
CR20240191A (es) 2024-09-13
CL2024001397A1 (es) 2024-10-25
JOP20240096A1 (ar) 2024-04-24
AU2022386486A1 (en) 2024-05-09
EP4430050A4 (en) 2025-09-24
WO2023083286A1 (en) 2023-05-19
US11739077B2 (en) 2023-08-29
US12570634B2 (en) 2026-03-10
CN119053601A (zh) 2024-11-29
EP4430050A1 (en) 2024-09-18
TW202334142A (zh) 2023-09-01
AR127646A1 (es) 2024-02-14
IL312642A (en) 2024-07-01
US20230183210A1 (en) 2023-06-15
KR20240117556A (ko) 2024-08-01
JP2024543477A (ja) 2024-11-21
DOP2024000080A (es) 2024-11-29
CO2024006269A2 (es) 2024-05-30

Similar Documents

Publication Publication Date Title
CA3235603A1 (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
CA3235765A1 (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
AU2022384416A1 (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2023114733A1 (en) Kras modulators and uses thereof
WO2022261210A1 (en) Kras modulators and uses thereof
TW477788B (en) Substituted heteroaromatic compounds and their methods for their preparation and use
RS60192B1 (sr) Inhibicija jonskog kanala a1 za prolazni receptorski potencijal
CN103748090A (zh) 糖苷衍生物及其用于治疗糖尿病的用途
WO2023249563A1 (en) Compounds and method for pkmyt1 inhibition
CA3208490A1 (en) Analogs for the treatment of disease
CN111655693A (zh) 抑制瞬时型感受器电位a1离子通道
US20230131192A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2023177356A2 (en) Compounds and method for pkmyt1 inhibition
CA3235762A1 (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
OA21706A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.
OA21707A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.
OA21708A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.
EA050901B1 (ru) Низкомолекулярные ингибиторы убиквитин-специфической протеазы 1 (usp1) и их применение
WO2023078337A1 (en) Cdk8/19 dual inhibitors and methods of use
WO2024236528A1 (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2025106014A1 (en) Compounds and methods for pkmyt1 inhibition
EP2426130B1 (en) Purine derivative and antitumor agent using same

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241030

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241030

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241030

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022